KMT2D and familial pancreatic carcinoma: In a study of pancreatic cancer, Koutsioumpa et al. [34] showed that KMT2D levels were downregulated in pancreatic tumors compared to normal pancreatic tissues and that KMT2D decreased glycolysis via downregulation of the glucose transporter SLC2A3 (alias GLUT3) to suppress tumorigenicity of pancreatic cancer cell lines.